Comparative Pharmacology
Head-to-head clinical analysis: CYCLAINE versus POSIMIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLAINE versus POSIMIR.
CYCLAINE vs POSIMIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclaine is a local anesthetic that reversibly blocks nerve conduction by decreasing the permeability of the neuronal membrane to sodium ions, thereby stabilizing the membrane and preventing the initiation and transmission of electrical impulses.
Bupivacaine, the active ingredient in POSIMIR, is an amide-type local anesthetic that blocks voltage-gated sodium channels in nerve cell membranes, inhibiting the generation and conduction of nerve impulses. POSIMIR is a bupivacaine extended-release liposomal formulation designed for sustained release at the surgical site.
0.2–0.4 mg/kg IV for induction; 0.5–1.5 mg/kg/h IV infusion for maintenance.
Posimir (bupivacaine) is administered as a single intra-articular injection into the subacromial space following arthroscopic shoulder surgery. The recommended adult dose is 5 mL (66 mg) of the 1.32% solution.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in adults; prolonged with hepatic impairment.
Terminal elimination half-life is approximately 27 hours (range 16-38 hours), supporting once-daily dosing in clinical use.
Renal: minimal (<5% unchanged); biliary/fecal: >70% as metabolites; small amount exhaled as CO2.
Primarily hepatic metabolism via CYP3A4 and CYP1A2 to inactive metabolites; <5% excreted unchanged in urine. Biliary/fecal excretion accounts for >90% of total clearance.
Category C
Category C
Local Anesthetic
Local Anesthetic